This research is Trending!
2023 ESC Guidelines for the management of endocarditis
Authors
Discussion
Loading...
Member takes
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“A really important message from the document is that once patients have reached a state of clinical stability, and we define what that stability is in the document, they can be switched to oral antibiotics rather than spending the entire 6 weeks in the hospital, which can be detrimental sometimes for patients.”
TVThomas van der VaartInternal medicine resident, Academic Medical Center Amsterdam
“The sensitivity of the new 2023 ESC criteria is 82.7% (vs 84.2% for Duke-ISCVID, P =.014) and the specificity is 92.3% (vs 93.9%, P =.083).”
“Patient education is therefore paramount to early diagnosis and treatment. Those with valvular heart disease or previous heart valve surgery should be particularly diligent with regards to prevention and recognizing symptoms.”
Implication
Supports multidisciplinary endocarditis care pathways; extends prior ESC guidance with integrated imaging criteria.
Key Points
- Management recommendations establish updated standards for endocarditis care, emphasizing interdisciplinary coordination and timely intervention.
- Guideline recommendations consolidate multi-expert consensus across cardiology, providing a unified clinical framework for endocarditis treatment.
- Highlights clinical decision pathways to improve outcomes in endocarditis, while calling for adherence to multidisciplinary endocarditis management.
Cite This Study
Delgado et al. (2023) studied this question. The 2023 ESC Guidelines provide updated, comprehensive clinical recommendations for the diagnosis, antimicrobial treatment, and surgical management of endocarditis.